bioRASI, LLC   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Hollywood FL United States (2002)

Organization Overview

First Clinical Trial
2013
NCT01948024
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

bioRASI, LLC

Active Ingredients

Drugs in Phase 3 Trials (5)

Key: bioRASI, LLC (4) Acquired (1)

alferminogene tadenovec (1 trial)

ivermectin (stromectol) (1 trial)

metronidazole (flagyl) (1 trial)

permethrin (nix) (2 trials)

podofilox (condylox) (1 trial)

Drugs in Phase 2 Trials (3)

allogeneic mesenchymal stem cells (1 trial)

b244 (2 trials)

rifaximin (xifaxan) (1 trial)

Drugs in Phase 1 Trials (1)

asenapine (saphris) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bipolar Disorder (Phase 1)

Condylomata Acuminata (Phase 3)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Lice Infestations (Phase 3)

Pruritus (Phase 2)

Rosacea (Phase 3)

Scabies (Phase 3)

Schizophrenia (Phase 1)

Warts (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 9